Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance

Restricted access

Rituximab has been proven to be an important part of the treatment of newly diagnosed and relapsed or refractory follicular lymphoma both alone and in combination with chemotherapy. Given its tolerability, rituximab has now been investigated in the maintenance setting in an effort to further improve progression-free and overall survival in patients with follicular lymphoma.

The authors have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturers of any products discussed in this article or their competitors. Correspondence: Rupali Roy, MD, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 North St. Clair, Suite 850, Chicago, IL 60611. E-mail: rupali-roy@md.northwestern.edu
  • 1

    MarcusRImrieKSolal-CelignyP. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol2008;26:45794586.

    • Search Google Scholar
    • Export Citation
  • 2

    HiddemannWKnebaMDreylingM. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood2005;106:37253732.

    • Search Google Scholar
    • Export Citation
  • 3

    HeroldMHaasASrockS. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol2007;25:19861992.

    • Search Google Scholar
    • Export Citation
  • 4

    SallesGMounierNde GuibertS. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood2008;112:48244831.

    • Search Google Scholar
    • Export Citation
  • 5

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood1997;89:39093918.

    • Search Google Scholar
    • Export Citation
  • 6

    FritzAPercyCJackA. International Classification of Diseases for Oncology (ICD-O)3rd ed.Geneva, Switzerland: World Health Organization; 2001.

    • Search Google Scholar
    • Export Citation
  • 7

    HorningSJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol1993;20:7588.

  • 8

    Solal-CelignyPRoyPColombatP. Follicular lymphoma international prognostic index. Blood2004;104:12581265.

  • 9

    BuskeCHosterEDreylingM. The Follicular Lymphoma International Prognostic Index separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone with respect to treatment outcome. Blood2006;108:15041508.

    • Search Google Scholar
    • Export Citation
  • 10

    FedericoMBelleiMMarcheselliL. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol2009;27:45554562.

    • Search Google Scholar
    • Export Citation
  • 11

    ArdeshnaKMSmithPNortonA. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet2003;362:516522.

    • Search Google Scholar
    • Export Citation
  • 12

    YoungRCLongoDLGlatsteinE. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol1988;25:1116.

    • Search Google Scholar
    • Export Citation
  • 13

    BricePBastionYLepageE. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol1997;15:11101117.

    • Search Google Scholar
    • Export Citation
  • 14

    GospodarowiczMKLippunerTPintilieM. Stage I and II follicular lymphoma: long-term outcome and pattern of failure following treatment with involved-field radiation therapy alone. Int J Radiat Oncol Biol Phys1999;45:217a.

    • Search Google Scholar
    • Export Citation
  • 15

    JohnsonPGlennieM. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol2003;30:38.

  • 16

    ReffMECarnerKChambersKS. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood1994;83:435445.

  • 17

    WinklerUJensenMManzkeO. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood1999;94:22172224.

    • Search Google Scholar
    • Export Citation
  • 18

    GolayJZaffaroniLVaccariT. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood2000;95:39003908.

    • Search Google Scholar
    • Export Citation
  • 19

    ClynesRATowersTLPrestaLGRavetchJV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med2000;6:443446.

  • 20

    CartronGDacheuxLSallesG. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood2002;99:754758.

    • Search Google Scholar
    • Export Citation
  • 21

    GhetieMABrightHVitettaES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood2001;97:13921398.

    • Search Google Scholar
    • Export Citation
  • 22

    ByrdJCKitadaSFlinnIW. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood2002;99:10381043.

    • Search Google Scholar
    • Export Citation
  • 23

    DemidemALamTAlasS. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm1997;12:177186.

    • Search Google Scholar
    • Export Citation
  • 24

    HilcheySPHyrienOMosmannTR. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood2009;113:38093812.

    • Search Google Scholar
    • Export Citation
  • 25

    McLaughlinPGrillo-LopezAJLinkBK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol1998;16:28252833.

    • Search Google Scholar
    • Export Citation
  • 26

    ColombatPSallesGBrousseN. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood2001;97:101106.

    • Search Google Scholar
    • Export Citation
  • 27

    LewisGMarcusREProctorSJ. The cost-effectiveness of rituximab, cyclophosphamide, vincristine, and prednisolone (RCVP) compared with CVP for the treatment of follicular non-Hodgkin’s lymphoma (NHL) in the UK [abstract]. Blood2006;108(Suppl 1):Abstract 345.

    • Search Google Scholar
    • Export Citation
  • 28

    DavisTAGrillo-LopezAJWhiteCA. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol2000;18:31353143.

    • Search Google Scholar
    • Export Citation
  • 29

    RohatinerAZGregoryWMPetersonB. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol2005;23:22152223.

    • Search Google Scholar
    • Export Citation
  • 30

    StewardWPCrowtherDMcWilliamLJ. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin’s lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer1988;61:441447.

    • Search Google Scholar
    • Export Citation
  • 31

    EzdinliEZHarringtonDPKucukO. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin’s lymphoma. Cancer1987;60:156160.

    • Search Google Scholar
    • Export Citation
  • 32

    MorschhauserFRadfordJVan HoofA. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol2008;26:51565164.

    • Search Google Scholar
    • Export Citation
  • 33

    HagenbeekARadfordJVan HoofA. 90Y-Ibritumomab tiuxetan (Zevalin) consolidation of first remission in advanced-stage follicular non-Hodgkin’s lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized, phase III First-Line Indolent Trial (FIT) in 414 patients [abstract]. Presented at the 52nd ASH Annual Meeting and Exposition; December 4–7, 2010; Orlando, Florida. Abstract 594.

    • Search Google Scholar
    • Export Citation
  • 34

    HainsworthJDLitchySBurrisHAIII. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol2002;20:42614267.

    • Search Google Scholar
    • Export Citation
  • 35

    GhielminiMSchmitzSFCogliattiSB. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood2004;103:44164423.

    • Search Google Scholar
    • Export Citation
  • 36

    HainsworthJDLitchySShafferDW. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol2005;23:10881095.

    • Search Google Scholar
    • Export Citation
  • 37

    HochsterHWellerEGascoyneRD. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol2009;27:16071614.

    • Search Google Scholar
    • Export Citation
  • 38

    ForstpointnerRUnterhaltMDreylingM. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood2006;108:40034008.

    • Search Google Scholar
    • Export Citation
  • 39

    van OersMHKlasaRMarcusRE. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood2006;108:32953301.

    • Search Google Scholar
    • Export Citation
  • 40

    van OersMHVan GlabbekeMGiurgeaL. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol2010;28:28532858.

    • Search Google Scholar
    • Export Citation
  • 41

    VidalLGafter-GviliALeiboviciL. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst2009;101:248255.

    • Search Google Scholar
    • Export Citation
  • 42

    MartinelliGSchmitzSFUtigerU. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol2010;28:44804484.

    • Search Google Scholar
    • Export Citation
  • 43

    SallesGSeymourJFOffnerF. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet2011;377:4251.

    • Search Google Scholar
    • Export Citation
  • 44

    GordanLNGrowWBPusateriA. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol2005;23:10961102.

    • Search Google Scholar
    • Export Citation
  • 45

    BerinsteinNLGrillo-LopezAJWhiteCA. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol1998;9:9951001.

    • Search Google Scholar
    • Export Citation
  • 46

    TavernaCJBassiSHitzF. First results of long-term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03 [abstract]. J Clin Oncol2009;27(15 Suppl):Abstract 8534.

    • Search Google Scholar
    • Export Citation
  • 47

    RaoAKellyMMusselmanM. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer2008;50:822825.

    • Search Google Scholar
    • Export Citation
  • 48

    AksoySHarputluogluHKilickapS. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma2007;48:13071312.

  • 49

    YeoWChanTCLeungNW. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol2009;27:605611.

    • Search Google Scholar
    • Export Citation
  • 50

    PeiSNChenCHLeeCM. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol2010;89:255262.

    • Search Google Scholar
    • Export Citation
  • 51

    ZiakasPDKarsaliakosPMylonakisE. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica2009;94:9981005.

    • Search Google Scholar
    • Export Citation
  • 52

    CarsonKREvensAMRicheyEA. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood2009;113:48344840.

    • Search Google Scholar
    • Export Citation
  • 53

    KimbyE. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev2005;31:456473.

  • 54

    WolachOBaireyOLahavM. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore)2010;89:308318.

    • Search Google Scholar
    • Export Citation
  • 55

    VoogEMorschhauserFSolal-CelignyP. Neutropenia in patients treated with rituximab. N Engl J Med2003;348:26912694.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 72 69 8
PDF Downloads 17 17 0
EPUB Downloads 0 0 0